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Class switch recombination imparts B cells with a fitness-associated adaptive  advantage 
during a humoral immune response by using a precision-tailored DNA excision and 
ligation process to swap the default constant region gene of the antibody with a new 
one that has unique effector functions. This secondary diversification of the antibody 
repertoire is a hallmark of the adaptability of B cells when confronted with environmental 
and pathogenic challenges. Given that the nucleotide sequence of genes during class 
switching remains unchanged (genetic constraints), it is logical and necessary therefore, 
to integrate the adaptability of B cells to an epigenetic state, which is dynamic and can 
be heritably modulated before, after, or even during an antibody-dependent immune 
response. Epigenetic regulation encompasses heritable changes that affect function 
(phenotype) without altering the sequence information embedded in a gene, and include 
histone, DNA and RNA modifications. Here, we review current literature on how B cells 
use an epigenetic code language as a means to ensure antibody plasticity in light of 
pathogenic insults.
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introduction
Genes are the basic molecular unit of heredity in all organisms since it is the gene (genotype) and not 
the trait (phenotype; except for imprinted genes) that is inherited. A gene usually refers to a particular 
sequence of nucleotides that has an annotated function. However, phenotypic manifestations can be 
governed by factors beyond (epi) genes (genetics), which too are hereditary. Epigenetic alterations 
are carried out by a repertoire of modifiers (writers and erasers) and readers, which can act on either 
proteins (histones) or nucleic acid (DNA/RNA) (1–3). Epigenetic regulation also includes non-coding 
RNAs (micro-RNA and long non-coding RNA), which can directly or indirectly (via recruitment of 
proteins) affect gene expression (4–6). This complex layer of gene regulation is a testament to the pli-
ability that the system needs and possesses. The immune system exemplifies one such complex system 
that is geared to adapt to the environment, and B cells that make antibodies also need to reshape 
their antibody repertoire during antigenic challenges. Thus, it is not surprising that B cells overcome 
genetic constraints and integrate environmental cues into a complex network of gene regulation, 
which is both flexible and heritable. Dynamic epigenetic alterations engineered with spatiotemporal 
precision that expand the genetic code beyond A, G, C, and T, would be ideal for B cells in their quest 
to diversify the antibody repertoire during infection by an ever-evolving array of pathogens.
Class switch recombination (CSR) is one such secondary antibody diversification that occurs in 
peripheral lymphoid organs when B cells encounter antigen, and is dependent on cytokine/chemokine 
cues generated by T cells and stromal cells (7). The switching of the antibody isotype from IgM (or IgD) 
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to IgG, IgE, or IgA is necessary to impart distinct effector functions 
(8, 9). At the molecular level, CSR is a deletional-recombination 
reaction occurring between repetitive DNA elements, called 
switch (S) regions that precede each constant region (CH) segment. 
Cytokine stimulation and/or antigen binding to B cells stimulate 
“germline” transcription through the S regions and promote acces-
sibility of the DNA deaminase AID (activation-induced cytidine 
deaminase), whose activity leads to the generation of DNA double-
strand breaks (DSBs) at S regions. End-joining of DSBs between 
donor (usually Sμ) and acceptor S (Sγ, Sε, or Sα) regions replaces 
Cμ for a different CH gene segment downstream of the rearranged 
variable region segment to complete CSR (Figure 1). The drivers 
of germline transcription, AID expression, its target specificity and 
factors in end-joining have been extensively studied and reviewed 
elsewhere in Ref. (8, 10–13).
The role of histone modifications, DNA methylation, and 
non-coding RNAs during CSR has been recognized and appreci-
ated significantly in the last decade (4, 14, 15). Given that B cells 
encounter an inflammatory milieu during an immune response 
and since the same cues can also program epigenetic changes, 
it suffices to say that there must be an underlying intricate 
chromatin network landscape, which is shaped to govern CSR. 
In this review, we will focus on recent advances that buttress the 
existence of epigenetic codes that orchestrate CSR.
epigenetic Control of Switch (S) Region 
Locus Accessibility and Antibody 
Response
S regions are highly repetitive G-rich sequences that precede 
each constant region gene. Transcription through these 
regions is necessary for CSR. However, constitutive (donor 
S region) and inducible (acceptor S region) transcription is 
associated either with a poised and dynamic epigenetic state, 
FiGURe 1 | Overview of CSR. Each of the CH genes is preceded  
by transcribed, repetitive DNA elements called switch (S) regions.  
AID mediated DNA deamination, followed by processing of  
deaminated cytidines by components of the base excision and  
mismatch repair machineries (UNG and Msh2, respectively) lead  
to the generation of DNA double-strand breaks. End-joining of  
double-strand breaks between donor and acceptor S regions  
completes CSR. Scheme for CSR to IgE is shown; block curved arrows 
indicate germline transcription from promoters upstream of Sμ and Sε; 
*represents a putative, but uncharacterized switch region upstream of Cδ.
respectively  (4). Donor S region (Sμ) has a transcriptionally 
active state even in naïve B cells, suggesting that it is poised 
for participation in CSR. Histone modifications like H3K4me3 
and H3K9ac are present at Sμ in naïve B cells and increases 
upon stimulation (16–19). These are marks associated with an 
open chromatin conformation that would favor accessibility of 
the CSR machinery including tethering AID to donor S region.
On the other hand, the acceptor S regions (Sγ1, Sγ3, Sγ2a, 
Sε, and Sα) are inaccessible to the CSR machinery at the basal 
state. When the B cell faces an antigenic challenge that provides 
CSR triggers including T cell help (CD40 ligation), pattern-
recognition receptor ligation and the cytokine milieu (IL4, 
TGFβ, retinoic acid, BAFF, and IFNγ), the cognate S acceptor 
region accumulate histone modifications that are permissive to 
transcription and accessibility of only the particular S acceptor 
participating in CSR. The alterations include removal of repressive 
chromatin marks (H3K9me3 and H3K27me3) and also induc-
tion of H3K9ac and H3K4me3 (Figure 2) (17, 18). Knockdown 
of histone chaperone FACT complex components (SSRP1 and 
SPT16), Spt6, and methyl transferases (Ash2 and Wdr5) in 
CH12F3 cells have revealed the pertinence of the histone marks 
in regulating locus accessibility and S region cleavage, and thus 
CSR to IgA, a function which extends beyond germline transcript 
induction (20–22). If the same holds true in primary B cells and 
is it generalizable for CSR to other antibody isotypes remains to 
be determined. Additionally, H3K9me3 mark found at donor S 
region can recruit HP1γ-KAP1 complex, which facilitates AID 
tethering (17). The enzyme Suv39h1, which is probably the his-
tone methyl transferase involved in the deposition of this histone 
mark, plays a positive role in inducing CSR to IgA, since deletion 
of the gene impairs IgA CSR in primary B cells without affecting 
GLT (23). It is not specifically clear as to why there is isotype 
specificity if H3K9me3 is a donor S region mark.
A word of caution in the interpretation of all these results is 
warranted since most of the studies show strong correlative but 
FiGURe 2 | The histone modifications on donor and acceptor S regions in naïve and activated B cells are shown.
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not direct causative evidence; genetic models targeting the histone 
modifying enzymes would be required to unequivocally support 
the claims. Even the use of genetic or pharmacologic approach to 
manipulate histone modifications might not provide conclusive 
proof of their specific role in locus accessibility due to functional 
promiscuity/essentiality of the enzymes. Future studies are nec-
essary to uncover the complex relationships that probably exist 
between multiple factors influenced by a single histone modifica-
tion, and how an ensemble of spatiotemporal histone modifica-
tions orchestrates CSR.
The function of mixed-lineage leukemia (MLL)-like H3K4 
methyl transferase complex in CSR was tested by deletion of a key 
component PTIP conditionally in B cells (24, 25). These studies 
revealed that compromised H3K4me and acetylation and global 
chromatin architectural changes associated with the loss of PTIP 
leads to decreased S region accessibility, germline transcription, 
and thus compromised CSR to multiple isotypes (24, 25).
The function of histone acetylation/deacetylation in B cells 
was uncovered by conditionally inactivating MOZ (H3K9 acetyl 
transferase) and HDAC-1 and -2 genes in mature B cells (26, 
27). Stage-specific MOZ deletion suggested that it is required for 
optimal GC response (proper affinity maturation and memory 
formation) (26, 28). HDAC-1/2 were absolutely necessary for the 
proliferative burst that B cells undergo during stimulation for 
CSR, and double-deficient B cells fail to divide and die by apopto-
sis when challenged with LPS + IL4 (29). In contrast, pharmaco-
logical intervention with HDAC inhibitors, butyrate and valproic 
acid, in vivo during T-dependent/independent antibody response 
and ex vivo, did not affect B cell proliferation and viability (30). 
However, they did block CSR and plasma cell differentiation by 
upregulating cognate micro-RNAs that dampen AID and Blimp1, 
critical for CSR and plasma cell differentiation, respectively. 
Interestingly, the therapeutic potential of HDAC inhibitors in 
treating antibody-mediated lupus was highlighted by the finding 
that they ameliorated disease and prolonged survival in a mouse 
model of lupus (30). Discrepancies between genetic and pharma-
cological approaches can be due to milder effect of inhibitors or 
more broad effects on multiple HDACs beside HDAC-1/2.
Finally, the function of polycomb repressive complex (PRC)-2 
component, Ezh2 (histone methyl transferase), which was shown 
to be necessary for B cell development (31), during GC response 
was tested by conditional inactivation of Ezh2 using Cγ1-cre (32, 
33). Two independent studies provided compelling evidence that 
the germinal center (GC) formation and consequent cell-fate deci-
sions including CSR, SHM, plasma cell differentiation and memory 
response are critically shaped by Ezh2 (32, 33). H3K27me3 and 
H3K4me3 ChIP-Seq in Ezh2-sufficient versus -deficient GC B 
cells revealed that Ezh2 negatively regulates terminal differentia-
tion by epigenetically (via PRC2) regulating Blimp1, Xbp1, and 
Irf4, and thus promotes long-lasting immunity by sustaining 
antibody diversification and memory B cell differentiation (26, 
33). Gain of function mutant Ezh2 alleles (found in lymphoma 
patients) cause GC hyperplasia in mice and cooperate with Bcl2 
to accelerate and sustain malignant transformation of GC B cells 
(32). Combinational therapeutic targeting of Ezh2 for specific B 
cell malignancies (GC-DLBCL) will definitely be enticing (32, 33).
epigenetic Control of AiD expression
AID is the key enzyme that is essential for CSR. It is probably 
one of the only proteins unique to stimulated mature B cells, and 
AID fate-mapping studies corroborate that physiologically func-
tional levels of expression are largely restricted to B cells (34). It 
instigates DNA lesions in the form of deaminated deoxycytidine 
(dC), i.e., deoxyuridine (dU) at donor and acceptor S regions, 
which is subsequently processed by the general base excision 
repair, mismatch repair machineries, and DNA end-processing 
enzymes, such as, Mre11 and CtIP to generate DNA DSBs (10). 
Since it can induce DSBs, it is a potential mutator, and thus, 
AID expression is stringently controlled at the transcriptional 
and post-translational levels (8, 12). However, herein we review 
epigenetic factors modulating AID expression.
At the epigenetic level, AID expression is controlled by DNA 
methylation–demethylation and micro-RNAs. The AID locus, 
especially the promoter sites for cognate stimuli-induced tran-
scriptional factors are hypermethylated in naïve B cells and the 
mark is reversibly modulated during different stages of B cell-fate 
program (35). Activated B cells or GC (GL7+Fas+) B cells acquire 
a permissive epigenetic landscape of hypomethylation that allows 
robust AID expression by STAT6, NF-κβ and Hox-C4 transcrip-
tion factors (4). Besides, phylogenetic footprinting, histone acety-
lation, and DNase1 hypersensitivity site (DHS)-mapping revealed 
that the AID locus is dynamically shaped during an ongoing 
immune response (36). Histone H3 acetylation is increased at 
AID regulatory regions upon in vitro stimulation of naïve B cells 
and in GC B cells. In activated B cells, a conserved non-coding 
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sequence 7kb downstream of the AID locus maps to a DHS and 
regulates AID expression positively, via the binding of a yet to be 
identified protein (36). However, AID is turned off epigenetically 
upon terminal differentiation, probably as a means to preserve 
antigen specificity of the antibody secreting B cells (36).
Post-transcriptional regulation of AID by micro-RNAs 155, 
181b, 93, and 361, provides an additional layer of safeguard 
against a potent genome mutator (12). miR155, is the best studied 
one, which suppresses aicda expression by binding to a canonical 
site on the 3′-UTR of aicda. Although miR155 has functions way 
beyond suppressing AID in B cells undergoing CSR, as evidenced 
by compromised CSR in absence of miR155, yet its specific effect 
on regulating AID is significant. Mutation of the miR155-binding 
site on aicda 3′-UTR leads to increased AID levels that potentiate 
cMyc-IgH translocations (37, 38). Besides, miR155 and AID lev-
els are inversely correlated in Burkitt’s lymphoma, and an IL10/
miR155 axis can potentially modulate AID expression during 
chronic inflammation and lymphomagenesis (39).
epigenetic Control of AiD Targeting
An enzyme like AID is a dual-edged sword; on one hand, it is 
mandatory for optimal humoral immunity but on the other, a 
threat to genomic integrity. Therefore, a normal B cell must del-
egate adequate layers of safeguard in addition to regulating AID 
expression, which would primarily target AID to the physiological 
targets. Genetic factors controlling AID targeting and function 
have been reviewed elsewhere in Ref. (12, 13, 40). Herein, we will 
focus on epigenetic guides of this potent mutator.
Histone Modifications
One way to limit the risk of collateral damage would be to 
sequester AID at hotspot target motifs. S regions are GC-rich and 
possess stretches of 5′-AGCT-3′, which are AID hotspots (13). 
These regions, when transcribed form stable R-loop structures 
that provide single-stranded DNA substrates for AID (10). An 
intriguing finding is that histone modifications, such as, H3S10 
phosphorylation induced in CSR-activated B cells have also 
been linked to R-loop formation (41). Stable R-loops formed 
during CSR stimulation of B cells at S regions also accumulate 
H3K9AcS10ph modification. The classical adaptor protein 
14-3-3, which has unique specificity for 5′-AGCT-3′ repeats and 
H3K9AcS10ph modification, also directly binds AID (42, 43). 
Thus, it is well poised to recruit AID to recombining S regions 
during CSR, thereby serving as transducers of the epigenetic code 
(4). It remains to be seen, however, if genome-wide occupancy 
of 14-3-3, H3K9AcS10ph, and AID overlap, or if 14-3-3 only 
functions during physiological AID targeting. Another study 
focused on the chromatin-bound AID-interactome to reveal that 
the RNA polymerase-associated factor (PAF) complex member 
LEO1 is required for efficient targeting of AID to Sμ in CH12F3A 
cells (44). It will be interesting to test if the function of LEO1 is 
also pertinent in B cells undergoing ex vivo CSR and more impor-
tantly in GC B cells. AID was also shown to bind the KAP1-HP1γ 
complex, the latter of which recognizes H3K9me3 (17). AID 
targeting was dependent on KAP1 and also on its association with 
HP1, since genetic manipulation studies clearly revealed that AID 
occupancy at Sμ was dampened due to loss of KAP1 alone or its 
interaction with HP1 (17).
Super-enhancers and Regulatory Clusters
Enhancers are classically defined as a class of DNA elements that 
function in promoting transcription of gene from a distance, 
and irrespective of their orientation with respect to the target 
gene (45). Advance is sequencing techniques like DHS mapping 
(Dnase-seq), ChIP-seq and 3C-5C, Hi-Seq in the last decades 
has enabled genome-wide characterization of enhancers. Key 
features include presence of Dnase1 hypersensitive sites, mul-
tiple transcription factor binding sites, histone modifications 
like H3K4me1 and H3K27Ac, and looping to contact promoter 
elements far apart in the genome (46). Essentially now, the pres-
ence of a chromatin profile as alluded to above is considered 
as a hallmark of enhancers, although to date these are strongly 
correlative yet not always functionally causative. A new class 
of regulatory DNA elements has been defined recently, termed 
super-enhancers or stretch-enhancers (47, 48). These are cell-
type specific enhancers that play a key role in establishing lineage 
or cell identity (47, 48). They are defined as clusters of large 
regulatory domains that have remarkable enrichment for tran-
scription factor and coactivator (Mediator) binding along with a 
characteristic chromatin landscape (nucleosome occupancy and 
histone modifications) (46). Since AID expression and CSR are 
unique to B cells, it would make sense to regulate this cell-type 
specific expression and targeting by integrating stimulation cues 
to topologically associated domains i.e., super-enhancers. Recent 
work from several laboratories has greatly advanced our under-
standing of AID targeting/mistargeting (49–51).
Using genome-wide sequencing approaches including GRO-
seq, DNase-seq, and ChIP-seq, AID targets were found to be 
mostly unique in different cell-types (B cells, MEFs) although 
they shared common features of being transcriptionally active 
regions. However, transcription alone was not sufficient to explain 
the distinct set of hotspot in MEF versus B cells (49). Analysis of 
genes transcribed in both cell-types but only targeted in one, led 
to identification of a shared set of epigenetic attributes including 
H3K27Ac and H3K36me3, which typify enhancers (49). Deep 
sequencing techniques allowed uncovering a remarkable overlap 
of AID target sites to regions of the genome that constitute 
super-enhancers (50, 51). The AID off-targets like Cd83 in CSR-
activated B cells map to regions enriched in chromatin marks, 
typical of super-enhancers, and lie within sites of convergent 
transcription (sense transcription from promoter of genes and 
anti-sense transcription from super-enhancer) (50, 51). A major-
ity of AID-instigated lesions (irrespective of cell-type) occurred 
at transcription start sites, which were connected over long dis-
tances to multiple topologically active “regulatory clusters” (51). 
A central theme that came out from these elegant studies is that 
the nuclear microenvironment, which can vary from one cell type 
to another (even between ex vivo CSR-activated B cells and GC 
B cells), greatly influences AID target selection, yet the targets do 
share the following commonalities: (a) highly transcribed super-
enhancers, (b) topologically interconnected clusters, and (c) sites 
of convergent transcription (50–52) (Figure 3). How these find-
ings fit the available models of stalled Pol-II (Spt5), 14-3-3, RNA 
FiGURe 3 | Regulatory clusters containing super-enhancers modulate 
AiD mistargeting. Convergent transcription between promoters of target 
gene and super-enhancers from topologically associated domains (TAD) 
allow access of AID to single-stranded DNA and promote off-target activity. 
DHS – Dnase1 hypersensitive sites.
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exosome, PTBP2-mediated AID targeting remains to be explored 
(8). Additionally, these strong correlative evidences should 
now be tested for causation using the CRISPR-Cas9 system by 
abrogating transcription or knocking out the eRNA transcripts, 
to query if it affects the mutational landscape in AID-expressing 
cells. Another open question is whether convergent transcription 
regulates physiological Ig locus targeting of AID during CSR. 
These exciting avenues remain to be explored and would be at 
the forefront of research of AID biology in the coming years.
Non-Coding RNA
AID, being a member of the APOBEC-family of enzymes, 
has long been known to be associated with RNA and RNA 
metabolism-associated factors, such as, RNA Pol-II, Spt5, 
RNA  exosome, PTBP2, and CTNNBL1 (8). Since AID activity 
has been strongly linked to transcription, R-loop formation and 
anti-sense RNA processing, a recent study delved into the details 
of how non-coding RNA biology can impact AID targeting (14). 
Using a mouse model of conditional inactivation of an essential 
component of the RNA exosome (Exosc3), it was revealed that 
the RNA exosome shapes the non-coding transcriptome in B 
cells in a way that allows AID to access sites of anti-sense and 
divergent transcription (14). This was true for many of the well-
characterized off-target sites of AID in B cells including Cd79b, 
Cd83, Pim1, IL4ra, and cMyc. However, the proposed model of 
divergently transcribed loci generating RNA exosome substrates 
facilitating single-stranded DNA access to AID is in contradic-
tion with the convergent transcription model (14, 50), and future 
work is necessary to address the discrepancies.
Another elegant finding of Exosc3 and 10 conditional dele-
tions in mature B cells was that it unraveled a novel role of this 
cellular RNA degradation factory in regulating enhancer (e) and 
super-enhancer (se) RNAs, which as discussed before might have 
a remarkable impact on AID mistargeting (14, 50, 51, 53). The 
genome-wide mapping of changes in non-coding RNA tran-
scriptome in RNA exosome-deficient B cells undergoing CSR 
led to the identification of a distal divergent eRNA-transcribing 
element (lncRNA-CSR) (53). Ablation of transcription from this 
element profoundly impacted looping-dependent long-range 
DNA interactions with IgH 3′ regulatory region super-enhancer 
and compromised CSR. Additionally, the RNA exosome appears 
to promote genomic integrity in activated B cells by chewing 
up genome-destabilizing R-loop structures that emanate from 
active enhancers and also by regulating chromatin silencing (53). 
Questions come to mind as to how the CSR-promoting R-loop 
structures at S regions are preserved temporally, and how the RNA 
exosome function in facilitating template strand deamination by 
AID is in unison with its more global functions in genomic integ-
rity (54). Nonetheless, these compelling studies have definitely 
united super-enhancer and ncRNA biology into B cell research, 
especially CSR, and will propel the field forward in coming years.
Co-transcriptional processes and factors including RNA pol-II 
stalling, RNA exosomes, and even eRNA/seRNA appear to rein-
force the transcription and R-loop dependent AID targeting model 
(12, 14, 16, 50, 51, 53, 54). It can be concluded that the requirement 
for transcription (convergent/divergent) for AID targeting/mistar-
geting has been testified. However, an intriguing finding predating 
the discovery of AID was that processing of switch transcripts by 
splicing was also necessary for CSR (55, 56). The role of transcript 
per  se was elusive and post-transcriptional/splicing mechanisms 
regulating CSR have been understudied. To address if the sterile 
switch transcripts have a role in CSR, a mouse model of debranch-
ing enzyme (DBR1) haploinsufficiency and a knockdown approach 
in CH12F3A cells was used (15). These experiments revealed 
that if the generation of the transcript, post lariat debranching is 
abrogated, without affecting transcription or splicing, still, CSR 
is substantially impaired. The defect in CSR in DBR knockdown 
cells could be fully rescued by providing the switch RNA in trans, 
buttressing specificity of the phenotype (15). The defect in CSR 
was attributable to a failure to recruit AID to S regions, suggesting 
that the RNA might act in trans to guide AID back to the DNA 
locus due to sequence complementarity. This was indeed true, 
because provision of Sα transcripts in trans (in DBR1 knockdown 
CH12F3A cells) although could rescue AID recruitment to Sα but 
failed to target AID to Sμ, and thus failed to rescue CSR.
The structural basis of AID binding to RNA was due to the 
ability of the S region RNA to fold into G-quadruplex structures, 
which could be recognized by a recognition motif in AID that has 
a conserved G133 residue (15). Interestingly, this residue was also 
mutated (G133V) in human patients with hyper IgM syndrome 
(57). Indeed, G133V AID could not be recruited to S regions in B 
cells and failed completely to rescue CSR in AID-deficient cells, 
despite being catalytically active, expressed at similar levels and 
having similar subcellular localization as WT AID (15). The model 
proposed based on these findings is that following transcription 
of the S regions, the spliced out lariat is debranched by DBR1, 
the debranched RNA assumes G-quadruplex structures, which 
facilitates AID binding and allows sequence- and structure-
specific recruitment of AID to DNA during CSR (Figure  4). 
This physiological targeting mechanism can have implications 
for off-target AID activity as well because primary transcripts of 
many off-target AID genes (compared to non-target ones) have 
the potential to form G-quadruplex structures (15).
FiGURe 4 | Post-splicing RNA-dependent targeting mechanism of 
AiD during CSR. Transcribed S region are spliced, debranched (by DBR1) 
and the switch RNA assumes G-quadruplex conformation that allows 
structure- and sequence-dependent AID targeting back to S region DNA
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This opens up the field with many questions: how does the 
hand-off of AID-RNA complex to the DNA take place, and how 
the co-transcriptional mechanisms of AID targeting are comple-
mented by this post-splicing mechanism to ensure a coordinated 
system enabling efficient CSR.
epigenetic Control of DNA Repair
The culmination of AID activity and lesion processing at recom-
bining S regions during CSR is the generation of DNA DSBs, 
which constitute one of the most toxic lesions in a cell. Every 
cell in the body has evolved highly efficient and elaborate system 
dedicated to repair DSBs in order to promote survival and pre-
vent translocations. However, a B cell faces a daunting challenge; 
not only does it have to repair the breaks to limit translocation 
potential, but it also has to time the process with such exquisite 
precision that it promotes long-range recombination. The 
non-homologous end-joining repair pathway is the most well-
characterized one that is used during CSR (10). However, other 
pathways, such as, homologous recombination and alternative 
end-joining also play a role albeit to a lesser extent (8). The func-
tion of major players (genetic) in the AID-induced DNA damage 
response/repair phase that allow recombination including ATM, 
H2AX, Ligase IV, 53BP1, and Rif1 have been studied in-depth 
and reviewed elsewhere in Ref. (8, 10, 11, 13).
DNA insults have to be dealt within the context of a highly 
organized chromatin microenvironment and it is rational to 
assume that DNA DSB repair would be modulated significantly 
by epigenetic factors (58–60). Histones and many other DNA 
repair proteins undergo different post-translational modifications 
(PTMs) including phosphorylation, ubiquitylation, acetylation, 
methylation, sumoylation, and PARylation during an active repair 
response (61). These modifications can serve multiple purposes 
including serving as scaffold to recruit essential DNA repair fac-
tors, many of which harbor complementary domains to recognize 
the PTM. The histone variant H2AX gets phosphorylated at Ser 
139 (γH2AX) in response to DNA damage by PI3K-like family 
of kinases (ATM, ATR, and DNA-PKcs), a classical DNA DSB 
marker. H2AX deficiency compromises CSR possibly due to defect 
in long-range chromatin remodeling and synapsis. BRCT domain 
containing proteins like MDC1 and 53BP1 also play an important 
role in the cascade of DNA repair events following DSB induction 
(62). MDC1, via its BRCT domain recognizes γH2AX and allows 
recruitment of E3 ubiquitin ligases RNF8 and RNF168, both of 
which are required for efficient CSR. The CSR defects are milder 
as compared to that in 53BP1-deficient B cells (63–65). 53BP1 
functions mainly to prevent resection of DNA ends by recruiting 
Rif1 (66), and allows for timely persistence of breaks to be joined in 
trans (to acceptor S regions) rather than in cis (intra-switch recom-
bination). 53BP1 recruitment to DNA is dependent on H4K20me2 
mark, which is recognized via its tudor domain. Mutation in the 
tudor domain leads to compromised CSR, implying that reading 
the chromatin mark is important in potentiating its function 
(67). 53BP1 has been recently shown to recognize DNA damage-
induced H2AK15 ubiquitylation (68), and it remains to be seen if 
this function also regulates CSR. The histone methyl transferase 
MMSET (WHSC1, implicated in Wolf-Hirschornn Syndrome) 
also functions during CSR, since knockdown of MMSET impairs 
53BP1 recruitment to DNA damage site and compromises CSR 
(69). Lastly, the bromo-domain reader, Brd4, was also shown to 
function during CSR by providing an ideal chromatin platform 
during DNA repair phase (70). Brd4 inhibitor JQ1 perturbed 
CSR by affecting 53BP1 accumulation and end-joining pathway 
choice (70). JQ1 also compromised in vivo GC response during 
T-dependent Ag challenge, and this was suggested to be due to fail-
ure of NF-kappa B signaling and Bcl6 upregulation (71). However 
JQ1 can have non-specific effects, and genetic or domain-specific 
mutational approaches to test Brd4 function must be employed in 
the future to establish its role in CSR.
The methyl cytosine dioxygenase family of enzymes (TETs), 
has been in focus for their ability to demethylate specific regions 
of the genome (indirectly, via conversion of methylated cytidines 
to hydroxymethylated cytidines followed by engagement of base-
excison repair) derepress genes (2). These TET enzymes have been 
found to be mutated or shut-off in many tumors, suggesting that 
they might have epigenetic tumor suppressive functions. Indeed, 
deletion of TET1 in mice was associated with increased propen-
sity of development of B cell lymphomas (72). TET1 was required 
for maintenance of normal 5hmC levels and distribution across 
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the genome, which allowed adequate expression of essential DNA 
repair genes (e.g., lig1, ogg1, rad50, and rad51). Absence of TET1 
led to increased γH2AX foci and DNA damage sensitivity due to 
lack of repair and potentiated lymphomagenesis (pre-malignant 
B lymphomas at pro-B cell stage) (72). Outstanding questions 
about the role of other TET enzymes (TET2 and TET3), and even 
AID as a demethylase in B cell physiology and pathology remain 
to be explored (73, 74).
Lastly, chromatin remodeling complexes too have been 
implicated in reorganizing the chromatin during CSR. Defects in 
INO80 nucleosome remodeler in humans and in CH12F3A cells 
compromises CSR, likely due to improper loading of the cohesion 
complex and synaptic complex formation (75). Indeed, defects in 
cohesion loading proteins do cause abrogation of CSR (76, 77). 
These findings need to be introspected further because INO80 
and cohesion complex have global cellular functions that extend 
beyond CSR.
Summary and Perspective
Taken together, a bevy of epigenetic factors including “histone 
codes”, ncRNA, micro-RNAs, and super-enhancers communicate 
and coordinate to provide a dynamic chromatin landscape, which 
is geared for optimal diversification of the antibody repertoire.
Advances in sequencing-based techniques and data from 
the ENCODE project have greatly propelled research in the last 
decade (78). B cell biology, especially CSR has been investigated 
at depths like never before, and this has revealed the complexities 
that underlie this mechanistically counterintuitive process, which 
the B cell has to accommodate as a cost for co-evolution with 
pathogens. The smooth collisions of the chromatin and enhancer 
landscapes that facilitate CSR have been unraveled, however a 
multitude of questions lie ahead.
New modifications of histones continue to be identified. For 
example, crotonylation (79), which is thought to be similar to 
acetylation in being catalyzed by p300 in presence of intracellular 
crotonyl-CoA (79, 80), and even its erasers have been identified 
(81). Given that histone acetylation has functions in CSR, it 
remains to be seen if and how crotonylation can modulate CSR. 
DNA methylation has been extensively studied over the years and 
its role in locus accessibility and gene expression (epigenomic) is 
well characterized. But recently there has been identification of 
RNA methylation (N6-methyl-adenosine) as an epitranscriptomic 
modification (1). Transcriptome-wide m6A-mapping has provided 
great insight into the prevalence and relevance of this RNA modi-
fication, and how it impacts gene expression (82). Identification of 
m6A “readers”, “writers” and “erasers” has also propelled epitran-
scriptomic research (82). Given that CSR is impacted significantly 
by an integral non-coding RNA (eRNA, seRNA, lncRNA, and 
micro-RNA) component, and that RNA methylation is more 
prominent in non-coding RNAs, it will be unsurprising if this 
modification impacts CSR (83–85). Additionally, a very recent 
identification of N6-methyl-deoxyadenosine modification in the 
DNA of lower eukaryotes as a new “epigenetic” mark also opens 
up the question whether the writers and erasers of this mark will 
impact CSR in higher eukaryotes (86–88).
Recent upsurge in research on the impact of microbiota on a 
multitude of processes in the immune system during health and 
disease has uncovered the significance of this symbiotic associa-
tion over centuries of evolution (89). Given that microbes have 
been shown to produce metabolites that functionally impact the 
epigenetic status of the host (90), it is tempting to speculate that 
even antibody responses in vivo will be epigenetically shaped by 
commensal-derived metabolites.
Most research reviewed herein has focused on positive regula-
tion of CSR. But, one aspect that has to be borne in mind is that 
in vivo, CSR is only one of the multiple cell-fates that a clonally 
expanding population of B cells undergoes. So, there has to be 
coordinated allocation to other cell-fates including plasma cell 
differentiation and memory B cell differentiation, possibly by 
negative modulation of CSR. There has to be active genetic and 
epigenetic modules that skew cell-fate decisions toward one 
versus another path. It is rational to presume that such fine-
tuning would be necessary in order to achieve an overall humoral 
response encompassing all aspects of adaptive immunity (adapt-
ability, specificity, and memory). Future research is warranted 
to understand molecular mechanisms of negative regulation of 
the individual modules of cell-fate decision programs in B cells 
during a GC response.
A programed DNA damage process, such as, CSR is rare and 
unique to B cells, the fundamental understanding of which will 
propel basic (understanding DNA repair, recombination, and 
immunity) and translational science (ontogeny of lymphomas 
and its therapies). Epigenetics undoubtedly has enormous 
influence on physiology (adaptive immunity) and pathology 
(autoimmunity and lymphomagenesis) (4). Thus, exciting times 
lie ahead for research in CSR due to the establishment of the solid 
framework of the epigenetic landscape governing CSR.
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